Media Center
Press Releases

Press Releases

13 Apr 17
Southeast Asian breast cancer market to hit $2.7 billion by 2022 as prevalence rate rises, says GBI Research

The Southeast Asian breast cancer market, which covers South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, is set to rise from $942.3 million in 2015 to $2.7 billion in 2022, representing a compound annual growth rate of 16.2%, according to business intelligence provider GBI Research.

Read post
11 Apr 17
Rheumatoid arthritis market in Southeast Asia to reach $1.44 billion by 2022, says GBI Research

The rheumatoid arthritis market in Southeast Asia, which covers South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, is set to grow from $1.04 billion in 2015 to $1.44 billion by 2022, representing a compound annual growth rate of 4.7%, according to business intelligence provider GBI Research.

Read post
20 Mar 17
Asia-Pacific non-small cell lung cancer market to soar to $6.2 billion by 2023, says GBI Research

The non-small cell lung cancer (NSCLC) market in the Asia-Pacific (APAC) region will more than double from $3 billion in 2016 to $6.2 billion by 2023, representing a substantial compound annual growth rate of 10.8%, according to business intelligence provider GBI Research.

Read post
16 Mar 17
As fatty liver disease prevalence soars, pharma companies look to first-in-class drugs, says GBI Research

Due to the increasing global prevalence of fatty liver disease (FLD), which comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), potentially leading to inflammation (steatohepatitis) and fibrosis, pharmaceutical companies are looking to first-in-class treatments to help to address increasingly urgent unmet needs, according to business intelligence provider GBI Research.

Read post
14 Mar 17
Global cancer supportive care therapeutics market to see negligible growth to $12.4 billion by 2022, says GBI Research

The global cancer supportive care market, which covers chemotherapy-induced neutropenia, chemotherapy-induced anemia, chemotherapy-induced nausea and vomiting, cancer pain, bone metastasis, and oral mucositis, is set to experience a low level of growth from $11.7 billion in 2015 to $12.4 billion by 2022, at a compound annual growth rate of 0.9%, according to business intelligence provider GBI Research.

Read post